- Third quarter total revenue of $22.1 million, up 26% year-over-year
- Positive cash flows, with Adjusted EBITDA(1) of $1.5 million, up 98% year-over-year, and our 27th consecutive quarter of positive Adjusted EBITDA
- Investor webinar scheduled for Thursday, November 13, 2025 at 10:00 AM ET / 7:00 AM PT
TORONTO, ONTARIO, November 13, 2025 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three and nine months ended September 30, 2025 and information regarding the Company’s investor webinar on Thursday, November 13, 2025. All figures are in Canadian dollars, unless otherwise noted.
“Our strong growth and improved cash flows demonstrate the work that our team has done to optimize our medical facility footprint, mitigate cost pressures, and increase the time our medical professionals are available to treat patients,” said Joe Walewicz, NeuPath’s Chief Executive Officer. “Our core clinic business is delivering on multiple fronts, with strong year-over-year growth in patient visits and rising demand for Arthrosamid®. We expect continued organic and inorganic growth for the balance of 2025 and beyond.”
Financial and Operational Highlights
- Total revenue was $22.1 million and $65.0 million for the three and nine months ended September 30, 2025, up 26% and 21% year-over-year;
- Adjusted EBITDA was $1.5 million and $5.0 million for the three and nine months ended September 30, 2025, up 98% and 71% year-over-year;
- For the nine months ended September 30, 2025, capacity utilization improved to 81%, up from 74% for the nine months ended September 30, 2024; and
- As at September 30, 2025, the Company had $4.6 million in cash and cash equivalents and interest-bearing long-term debt of $6.3 million.
- Non-International Financial Reporting Standard (“IFRS”) and Other Financial Measures defined by the Company below.
View entire press release – PDF